Back to Search Start Over

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.

Authors :
Caggiari, Laura
Miolo, Gianmaria
Buonadonna, Angela
Basile, Debora
Santeufemia, Davide A.
Cossu, Antonio
Palmieri, Giuseppe
De Zorzi, Mariangela
Fornasarig, Mara
Alessandrini, Lara
Canzonieri, Vincenzo
Lo Re, Giovanni
Puglisi, Fabio
Steffan, Agostino
Cannizzaro, Renato
De Re, Valli
Source :
International Journal of Molecular Sciences; Jan2018, Vol. 19 Issue 1, p47, 15p, 1 Diagram, 4 Charts, 2 Graphs
Publication Year :
2018

Abstract

The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
19
Issue :
1
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
127768748
Full Text :
https://doi.org/10.3390/ijms19010047